Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said that a pre-specified interim analysis of data from its HeartMate II Destination Therapy (DT) pivotal trial shows that patients implanted with
[Sadece Üyeler Görebilir. Üye olmak için tiklayiniz...]